Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS).

Full DD Report for MRNS

You must become a subscriber to view this report.


Recent News from (NASDAQ: MRNS)

Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
RADNOR, Pa., May 14, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Off...
Source: GlobeNewswire
Date: May, 14 2018 07:30
How To Use Probabilities In Investing: Open Sources
(In whose favor are the odds of this particular game, hmm? Image by Own work, CC BY-SA 3.0, source ) By John Leonard, CFA “The upcoming Powerball lottery is $100M. A ticket costs $1. With a 50% chance of winning I calculate an expected value for this trade of ~$50M. Having an IR...
Source: SeekingAlpha
Date: May, 11 2018 10:00
Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals - Fundamental Analysis, Key Performance Indications
NEW YORK, May 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE Capital Corporation (NYSE:STOR), Microvision, Inc. (NASDAQ:MVIS), In...
Source: GlobeNewswire
Date: May, 11 2018 08:25
Lucky Seven: An Introduction To My Top Biotechnology Picks
Introduction I am a Registered Nurse, currently advancing my education at Purdue University. I work on an intermediate care unit in a hospital where I am responsible for the care and lives of folks who come to me with a myriad of medical conditions. I hope to soon become a nursing professor....
Source: SeekingAlpha
Date: May, 03 2018 05:28
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
RADNOR, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provi...
Source: GlobeNewswire
Date: May, 02 2018 07:30
Vistagen - Nanocap CNS Drug Chasing Ketamine Fame
Vistagen ( VTGN ) is a strange company that has been around quite a while. They've developed some stem-cell research platforms with the help of Dr. Gordon Keller, but that particular platform has never really amounted to much success. There is some hope that it could potentially provide reve...
Source: SeekingAlpha
Date: March, 21 2018 13:49
Midday Gainers / Losers (03/20/2018)
ARNA +33% . CRME +24% . MULE +21% . SRI +19% . ACMR +15% . MDWD +16% . CASI +15% . MRNS +14% . PAR +14% . VSLR +13% . HQY +12% . More news on: Arena Pharmaceuticals, Inc., Cardiome Pharma Corporation, MuleSoft, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 20 2018 12:45
Premarket Gainers as of 9:05 am (03/20/2018)
CRME +37%  on divest Canadian business to Cipher Pharma for C$25.5M. More news on: Cardiome Pharma Corporation, Arena Pharmaceuticals, Inc., CHF Solutions, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 20 2018 09:12
After Hours Gainers / Losers (3/19/2018)
Top gainers: ARNA +24.6% . ELGX +8.1% . HLIT +6.4% . AMTX +6.2% . MRNS +6.1% . More news on: Arena Pharmaceuticals, Inc., Endologix Inc, Harmonic Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: March, 19 2018 17:41
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
RADNOR, Pa., March 08, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward F. Smith, Chief Financial Officer ...
Source: GlobeNewswire
Date: March, 08 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-135.875.976.025.75227,458
2018-08-105.925.866.065.73300,645
2018-08-096.005.976.115.86321,006
2018-08-085.856.016.065.73535,490
2018-08-075.685.876.005.48591,850

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1351,71065,93978.4210Short
2018-08-1046,35280,26257.7509Short
2018-08-0953,78178,40668.5930Short
2018-08-08112,219182,45361.5057Short
2018-08-07159,608221,60872.0227Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MRNS.


About Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

Logo for Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: MRNS)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 07 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: MRNS)

      Daily Technical Chart for (NASDAQ: MRNS)


      Stay tuned for daily updates and more on (NASDAQ: MRNS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: MRNS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MRNS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of MRNS and does not buy, sell, or trade any shares of MRNS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/